The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
1
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA.
2
Center for Liver Disease and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA.
Abstract
Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%. Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States. As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH. Therefore, the transplant team must be well versed in the state of current knowledge about NAFLD and transplant-specific issues for this increasingly important indication for LT.